Peramivir

	Influenza Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Influenza from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Peramivir On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Peramivir All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Peramivir
CDC on Peramivir
Peramivir in the news
Blogs on Peramivir
Directions to Hospitals Treating Influenza
Risk calculators and risk factors for Peramivir

Peramivir
	File:Peramivir.png
Identifiers
	IUPAC name (1S,2S,3S,4R)-3-[(1S)-1-Acetamido-2-ethyl-butyl] -4-(diaminomethylideneamino)-2-hydroxy-cyclopentane -1-carboxylic acid;
CAS Number	229614-55-5;
PubChem CID	151164;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C15H28N4O4
Molar mass	328.407 g/mol

Peramivir is an experimental antiviral drug being developed by Biocryst Pharmaceuticals to treat influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. The development of peramivir is supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic.^[1]

The drug has had a long history. An oral formulation was abandoned by Johnson and Johnson due to poor bioavailability.^[2] BioCryst is now developing a injectable version, in partnership with Green Cross Pharmaceuticals in South Korea and with Shionogi Pharmaceuticals in Japan. The drug is in Phase II studies.^[3] ^[4]

Experimental data indicate that peramivir may have useful activity against many viruses of interest, including H5N1 (avian bird flu) , hepatitis B, polio, measles and smallpox. Peramivir is active in a hamster model of yellow fever, a finding which is not surprising, given the familial relationship of yellow fever and hepatitis C viruses as flaviviridae. Peramivir is active against other important flaviviridae such as West Nile virus and dengue fever.Template:Facts

Sources

↑ "HHS Pursues Advance Development of New Influenza Antiviral Drug" (Press release). US Department of Health and Human Services. 2007-01-04. Retrieved 2007-05-25. Check date values in: |date= (help)
↑ Pollack, Andrew (2005-10-07). "Talk of Bird Flu Pandemic Revives Interest in Passed-Over Drugs". New York Times. Retrieved 2007-05-25. Check date values in: |date= (help)
↑ "Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza". National Institutes of Health. 2007-03-16. Retrieved 2007-05-25. Check date values in: |date= (help)
↑ "Evaluation of the Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-Threatening Influenza". National Institutes of Health. 2007-03-28. Retrieved 2007-05-25. Check date values in: |date= (help)

This antimicrobial-related article is a stub. You can help Wikipedia by expanding it.

Template:WikiDoc Sources

[1] "HHS Pursues Advance Development of New Influenza Antiviral Drug" (Press release). US Department of Health and Human Services. 2007-01-04. Retrieved 2007-05-25. Check date values in: |date= (help)

[2] Pollack, Andrew (2005-10-07). "Talk of Bird Flu Pandemic Revives Interest in Passed-Over Drugs". New York Times. Retrieved 2007-05-25. Check date values in: |date= (help)

[3] "Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza". National Institutes of Health. 2007-03-16. Retrieved 2007-05-25. Check date values in: |date= (help)

[4] "Evaluation of the Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-Threatening Influenza". National Institutes of Health. 2007-03-28. Retrieved 2007-05-25. Check date values in: |date= (help)

[1]

[2]

[3]

[4]

v t e Antivirals, other than for HIV (primarily J05, also S01AD and D06BB)
Anti-herpesvirus (DNA, I)	guanine analogues (Aciclovir, Famciclovir, Ganciclovir, Penciclovir, Valaciclovir, Valganciclovir) • nucleoside analogues (Idoxuridine, Trifluridine, Vidarabine) • Cidofovir • Docosanol • Fomivirsen • Foscarnet • Tromantadine
HPV/MC (DNA, I)	Imiquimod • Podophyllotoxin
Hepatitis B (DNA, VII)	Adefovir • Interferon alfa-2b • Pegylated interferon alfa-2a • Entecavir • Lamivudine • Telbivudine • Tenofovir^†
Hepatitis C (RNA, IV)	Pegylated interferon alpha • Ribavirin • Taribavirin^† • Boceprevir^†
Picornavirus (RNA, IV)	Pleconaril^†
Anti-influenza agents (RNA, V)	Arbidol adamantane derivatives/M2 inhibitors (Amantadine, Rimantadine) neuraminidase inhibitors (Oseltamivir, Zanamivir, Peramivir^†)
HIV (Reverse, VI)	See HIV pharm
Other antiviral agents	general (Inosine, Interferon)
^†Undergoing clinical trials, not FDA approved.

Identifiers
File:Peramivir.png
IUPAC name (1S,2S,3S,4R)-3-[(1S)-1-Acetamido-2-ethyl-butyl] -4-(diaminomethylideneamino)-2-hydroxy-cyclopentane -1-carboxylic acid
CAS Number	229614-55-5
PubChem CID	151164
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₅H₂₈N₄O₄
Molar mass	328.407 g/mol

Peramivir

Sources

Navigation menu